At a glance
ClinicalIndex Comparison RecordPhase 2Active· 34 enrolled
Drug / intervention
Cabozantinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC)
In Brief
A Phase 2 clinical trial evaluating Cabozantinib and Pembrolizumab for Gastric Adenocarcinoma and GastroEsophageal Cancer. Active but no longer recruiting, targeting 34 participants across 1 site.
Detailed Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Adenocarcinoma, GastroEsophageal Cancer
CountriesUnited States
CollaboratorsExelixis
Timeline
Phase 2ActiveOverdue
2020202120222023202420252026
First PostedNov 2019
Enrollment StartFeb 2020
Primary CompletionNov 2023
Study CompletionMay 2026
TodayJul 2026
First PostedNov 15, 2019
Enrollment StartFeb 4, 2020
Primary CompletionNov 25, 2023
Study CompletionMay 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.6 years ago
Interventions
Cabozantinibdrug
Given PO
Pembrolizumabdrug
Given IV